Eisai Signs Bendamustine Deal With Symbio In Singapore And Korea, Highlighting Asian Oncology Market Potential
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based biotech start-up Symbio will grant exclusive development and marketing rights for non-Hodgkin's lymphoma drug bendamustine to Japan's fourth-largest drug maker Eisai in both Korea and Singapore
You may also be interested in...
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications
Japan Market Approval On Track For All-Case Surveillance Drugs From Lilly, GSK, Otsuka
TOKYO - A string of drugs are on track for marketing approval in Japan, as the pharmaceutical subcommittee of the Pharmaceutical Affairs and Food Sanitation Council confirmed its consent for approval of 22 new drugs and additional indications
Eisai To Reinforce Oncology R&D, Sales To Achieve 17% Income Rise
TOKYO - Quadrupling profits in the business year from the preceding year and forecasting a solid 17.5 percent rise in the current year, Eisai Co., the fourth-largest Japanese pharma and the only one reporting profit among the four, said it will further reinforce its oncology drug development and sales while accelerating global distribution of Alzheimer's treatment Aricept